This hybrid structure increased the efficacy of PD-1/PD-L1 inhibitors, and their combination with anti-PDL1 antibodies inhibited AML cell growth and regression in leukemia-bearing mice, which significantly increased their survival [88]. This evidence concerns the gene CD274 and leukemia.